B2B automotive aftermarket platform CassTime has garnered $35 million in a Series C3 round funding led by Source Code Capital, while Denovo Biopharma has pocketed nearly 300 million yuan ($46 million) in a Series D round co-led by CICC Qide and Yingke PE.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in